Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603004 · ClinicalTrials.gov registry record
Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
A clinical trial of Pancreatic Neuroendocrine Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT01603004: Completed study of Pancreatic Neuroendocrine Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01603004 is a study of Pancreatic Neuroendocrine Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603004, a study of Pancreatic Neuroendocrine Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Sunitinib and everolimus are two new treatments approved in 2011 for patients with pancreatic neuroendocrine tumors (NETs). In addition, some traditional chemotherapies are often used to treat pancreatic NETs. Traditional chemotherapy is also known as "cytotoxic therapy" and works by killing cells that are actively dividing. There have been no studies to compare the different types of treatment. Since the patient is eligible for treatment with either sunitinib, everolimus or traditional chemotherapy it can help us identify factors that may help future patients benefit from these therapies.
Primary Outcome
standard MRI sequences will be performed, according to guidelines from RECIST 1.1.
Conditions Studied
Interventions
- OTHER MRI
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-05-14 |
| Est. Completion | 2019-06-24 |
What the finished NCT01603004 record still lists
NCT01603004 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 1 condition, with Pancreatic Neuroendocrine Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.
NCT01603004 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01603004 about?
NCT01603004 is a clinical study titled "Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors". Sunitinib and everolimus are two new treatments approved in 2011 for patients with pancreatic neuroendocrine tumors (NETs). In addition, some traditional chemotherapies are often used to treat pancreatic NETs. Traditional chemotherapy is also known as "cytotoxic therapy" and works by killing cells t...
What is the current status of trial NCT01603004?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2012-05-14. Estimated completion is 2019-06-24.
What conditions does trial NCT01603004 study?
This clinical trial studies the following conditions: Pancreatic Neuroendocrine Cancer.
What interventions are being tested in trial NCT01603004?
The interventions under investigation include: MRI (OTHER).
Who is sponsoring clinical trial NCT01603004?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01603004 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI